- General abstract submission deadline is Monday, June 26, 2017.
- Participants will be notified on Monday, July 24, 2017 of their inclusion in the program.
- At least one author must be registered for the meeting in order for an abstract to be included in the program book.
ICE-HBV and the WHO Collaborating Centre for Viral Hepatitis at the Peter Doherty Institute for Infection and Immunity are organising a World Hepatitis Day symposium entitled From Vaccine to Cure: The Road to Viral Hepatitis Elimination.
Join us on 28 July from 2pm to 6pm, in person or online via Zoom. Please register here: https://goo.gl/2noLVa (free). Check the preliminary programme.
To participate to World Hepatitis Day campaign which will be displayed during the event, please create your own poster using this link and send it to firstname.lastname@example.org or tweet @ICE_HBV
All events related to World Hepatitis Day in Victoria can be found on Hepatitis Victoria website.
In collaboration with:
ICE-HBV manifesto was selected as one of the 180 scientific findings published in 2016 that editors believe could have the greatest impact on society’s most pressing problems.
It is free-access until the end of July on:
Following ICE-HBV’s request to Anthony Fauci to consider strengthening HBV research programmes and subsequent discussions, we received the following statement from John J. McGowan, Ph.D., Deputy Director for Science Management at NIAID:
We at the National Institute of Allergy and Infectious Diseases (NIAID) agree that chronic hepatitis B infection remains a major problem globally. In the United States as well as in other developed and developing countries, too few are vaccinated. The result is that millions with chronic disease will require treatment to prevent end-stage liver disease, cancer and an early death. NIAID supports a broad hepatitis B research portfolio, including basic research supported through R01 and R21 grants, drug and animal model development through small business grants, and the availability of a comprehensive array of preclinical services. In addition, NIAID has a current initiative PAR-14-255 (Multidisciplinary Studies of HIV and Viral Hepatitis Co-infection) with a final receipt date in May of 2017. NIAID also has two new concepts that were approved by the NIAID Advisory Council in January 2017:
- HIV and Hepatitis B Co-Infection: Advancing HBV Functional Cure through Clinical Research – R01 and R21
- In Vitro and Animal Model Studies on HBV/HIV Co-Infection – R01 and R21
You also should be aware of the SBIR initiative launched by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) entitled “New Technologies for Viral Hepatitis SBIR (R43/R44)”.
(NIAID staff) will continue to work with you to address the challenges we face as a community.
ICE-HBV Governing Board will keep approaching research institutes and foundations to request a scaling-up of HBV research programmes worldwide.
In May 2016, the World Health Assembly endorsed the Global Health Sector Strategy (GHSS) on viral hepatitis 2016–2021. The GHSS calls for the elimination of viral hepatitis as a public health threat by 2030 (reducing new infections by 90% and mortality by 65%).
This WHO Global hepatitis report describes, for the ﬁrst time, the global and regional estimates on viral hepatitis in 2015, setting the baseline for tracking progress in implementing the new global strategy.
The report focuses on hepatitis B and C, which are responsible for 96% of all hepatitis mortality. It presents data along the ﬁve strategic directions (strategic information, interventions, equity, ﬁnancing and innovation) – key pillars of the GHSS to facilitate monitoring of progress in countries, regions and globally, and to measure the impact of interventions on reducing new infections and saving lives between 2015 and 2030.